Chemistry:Visilizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD3 receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| (verify) | |
Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.[1]
PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] (As of July 2009).
Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.[6]
References
- ↑ "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". http://www.pdl.com/index.cfm?navId=43.
- ↑ "PDL Lands in a Hazard". 29 August 2007. http://www.fool.com/investing/high-growth/2007/08/29/pdl-lands-in-the-hazard.aspx.
- ↑ Clinical trial number NCT00938626 for "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma" at ClinicalTrials.gov
- ↑ "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/Metabolism Research and Reviews 25 (4): 302–6. May 2009. doi:10.1002/dmrr.933. PMID 19319985.
- ↑ Clinical trial number NCT00378508 for "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes" at ClinicalTrials.gov
- ↑ "Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes". Journal of Nuclear Medicine 50 (10): 1683–91. October 2009. doi:10.2967/jnumed.108.059485. PMID 19759100. https://art.torvergata.it/bitstream/2108/38880/3/J%20nucl%20med%202009.pdf.
 |  |
